Here, we systematically review observational studies of FLD, FED, and heterozygous subjects, which summarize available evidence on the natural history and biomarkers of LCAT deficiency, in order to guide the development of novel therapeutics. This evidence concerns the gene LCAT and hyperinsulinemic hypoglycemia, familial, 4.